

Latuda® (lurasidone) – First-time generic

- On February 20, 2023, <u>Accord</u>, <u>Amneal</u>, <u>Dr. Reddy's</u>, <u>MSN/Novadoz</u>, <u>Sun</u>, <u>Alkem/Ascend</u>, <u>Zydus</u>, and <u>Lupin launched</u> AB-rated generic versions of Sunovion's <u>Latuda</u> (<u>lurasidone</u>) tablets.
- Latuda is approved for:
 - Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia
 - Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression)
 - Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression).
- According to IQVIA, Latuda had estimated annual sales of \$4.2 billion in the U.S.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.